NCT06383559View on ClinicalTrials.gov

Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

July 1, 2026

Study Completion Date

September 1, 2026

Conditions
Gastric Cancer
Interventions
DRUG

Lenvatinib and Sintilimab

XELOX regimen combined with Sintilimab and Lenvatinib

Trial Locations (1)

Unknown

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER